SCHEMBL13628477

SCHEMBL13628477

C=C(C)[C@@H]1CC[C@]2(C(=O)NCc3cccc(C(=O)NCCCCC(=O)O)c3)CC[C@]3(C)C(CCC4[C@@]5(C)CCC(=O)C(C)(C)C5CC[C@]43C)C12

nearest known ligand 0.58

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ GPBAR1 Q8TDU6 3/20 0.58
▸ LMNA P02545 1/20 0.58
▸ NT5E P21589 1/20 0.58
▸ SMN1; SMN2 Q16637 1/20 0.58
▸ TRPV1 Q8NER1 1/20 0.52
▸ RORC P51449 7/20 0.49
▸ MGAM O43451 1/20 0.49
▸ GAA P10253 1/20 0.49
▸ SI P14410 1/20 0.49
▸ MGAM2 Q2M2H8 1/20 0.49
▸ EGLN2 Q96KS0 1/20 0.48
▸ EGLN1 Q9GZT9 1/20 0.48
▸ EGLN3 Q9H6Z9 1/20 0.48
▸ P4HTM Q9NXG6 1/20 0.48
▸ CETP P11597 1/20 0.47
▸ PRKCG P05129 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13637791 1.00 GPBAR1 (0.58) GPBAR1LMNANT5ESMN1; SMN2TRPV1
SCHEMBL4445877 0.89 TRPV1 (0.66) GPBAR1LMNANT5ETRPV1RORC
SCHEMBL13637465 0.89 TRPV1 (0.66) GPBAR1LMNANT5ETRPV1RORC
SCHEMBL13628320 0.89 TRPV1 (0.66) GPBAR1LMNANT5ETRPV1RORC
SCHEMBL13637460 0.89 TRPV1 (0.65) GPBAR1LMNANT5ETRPV1RORC
SCHEMBL13628322 0.89 TRPV1 (0.65) GPBAR1LMNANT5ETRPV1RORC
SCHEMBL14049880 0.88 HSD17B10 (0.42) GPBAR1LMNANT5ESMN1; SMN2TRPV1
SCHEMBL9128062 0.87 GPBAR1 (0.72) GPBAR1LMNANT5ESMN1; SMN2RORC
SCHEMBL13628323 0.85 TRPV1 (0.68) GPBAR1LMNANT5ETRPV1RORC
SCHEMBL13637709 0.85 TRPV1 (0.68) GPBAR1LMNANT5ETRPV1RORC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090275583-A1 ANTIVIRAL COMPOUNDS AND USE THEREOF MYRIAD GENETICS, INCORPORATED (US) 2009-11-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275583-A1 ANTIVIRAL COMPOUNDS AND USE THEREOF MAVS, ZC3HAV1, EIF2AK2 GPBAR1 3262/4885LMNA 2620/4885NT5E 304/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback